Yasim Rahimi's questions to Crinetics Pharmaceuticals Inc (CRNX) leadership • Q2 2025
Question
An analyst on behalf of Yasim Rahimi of Piper Sandler Companies asked if Crinetics plans to provide color on paltusotine's pricing at the time of approval and what has been learned from payer discussions about pricing flexibility compared to current injectable SRLs.
Answer
CEO R. Scott Struthers deferred the pricing discussion until after a potential approval. Chief Commercial Officer Isabel Kalofonos added that payer discussions have been positive, with payers recognizing the high treatment burden and waste associated with current SRLs. She confirmed the company is not commenting further on price at this time.